Reuters logo
CORRECTED-Novartis lung drug not inferior to GSK's Seretide, study shows
April 25, 2014 / 5:46 AM / 4 years ago

CORRECTED-Novartis lung drug not inferior to GSK's Seretide, study shows

(Removes paragraph on QVA149, which refers to Ultibro Breezhaler not Onbrez Breezhaler)

ZURICH, April 25 (Reuters) - Patients taking Novartis’ inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline’s Seretide, the Swiss drugmaker said on Friday, citing a late stage study.

The Phase IV study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis’ once-daily drug showed similar benefits in reducing shortness of breath as GSK’s Seretide, which must be taken twice daily.

Around 210 million people worldwide suffer from COPD, a disease that causes breathing trouble and chronic coughing, and is sometimes fatal. (Reporting by Caroline Copley; Editing by Edwina Gibbs and Jane Baird)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below